ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure
NCT00610051
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
600
Enrollment
INDUSTRY
Sponsor class
Conditions
End Stage Cardiac Failure
HFrEF - Heart Failure With Reduced Ejection Fraction
NYHF Class III-IV
Interventions
DRUG:
Alprostadil
Sponsor
Biopeutics Co., Ltd